NEW HAVEN, Conn., Jan. 7, 2009 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of Joseph Truitt as Vice President of Business Development and Chief Commercial Officer. Mr. Truitt, who joins Achillion from ViroPharma, Inc. which recently acquired Lev Pharmaceuticals, Inc., will be responsible for identifying, evaluating and executing corporate partnerships, strategic initiatives and new product opportunities.
